Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

v3.8.0.1
Commitments and Contingencies (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 14, 2017
Dec. 31, 2015
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Jun. 30, 2015
Dec. 30, 2013
Apr. 30, 2013
Commitments and Contingencies [Line Items]                  
Research and Development Expense, Total     $ 993,000 $ 1,049,000 $ 1,978,000 $ 1,869,000      
Royalty Guarantees, Commitments, Amount     200,000   $ 200,000        
Long Term Purchase Commitment Expire Date         Dec. 31, 2015        
Commitments [Member]                  
Commitments and Contingencies [Line Items]                  
Research Services Agreements Value Fulfilling Commitment   $ 3,000,000              
License Costs $ 30,627                
Initial license fee 20,000                
Contractual Obligation, Due in Next Twelve Months               $ 78,000  
Contractual Obligation, Due in Second Year               $ 161,754  
Settlement Agreement [Member]                  
Commitments and Contingencies [Line Items]                  
Prepaid Expense                 $ 1,000,000
Amended Agreement [Member]                  
Commitments and Contingencies [Line Items]                  
Research and Development Expense, Total             $ 2,100,000    
Minimum [Member] | Commitments [Member]                  
Commitments and Contingencies [Line Items]                  
License Costs 25,000                
Maximum [Member] | Commitments [Member]                  
Commitments and Contingencies [Line Items]                  
License Costs $ 150,000                
Fraunhofer [Member]                  
Commitments and Contingencies [Line Items]                  
Royalty Guarantees, Commitments, Amount     $ 4,000,000   $ 4,000,000        
Other Commitments, Description         the 2013 Settlement Agreement provided that, for a period of up to 15 years, the Company would pay Fraunhofer one percent (1%) of all receipts derived by the Company from sales of products produced utilizing the iBioLaunch or iBioModulator technology and ten percent (10%) of all receipts derived by the Company from licensing those technologies to third parties.